Long-form research on micro and small-cap companies, the ones the algorithms have not found yet. Every report shows its work: the model rebuilt from the filings, the footnotes read in full, our positions and sponsorships disclosed in every issue. Read by 12,400+ investors.
Revenue quality, unit economics, capital allocation, share count. If the numbers do not hold, the story does not get written.
Most analysts cover the same 500 names. We work the long tail: micro and small caps under $1B across biotech, software, energy, mining, and industrials.
Micro Math Capital is operated by Apollo Shareholder Relations. Sponsored coverage is labelled Sponsored. When we hold a position, the report says so. You always know what you are reading.
Our latest long-form report, built to outlast the news cycle.
Biotech capital in 2026 has demonstrated unusual appetite at the intersection of cardiology and inflammatory pathways. We trace the deal flow, the underlying science, and the small handful of companies positioned at the front of the wave.
We do not chase narrative, we measure it. Every report follows the same four stages: screen, filings, model, publish, with positions disclosed in every issue.
Read about our approach →We start with the long tail — companies under $1B that pass our quality screens for growth, margins, and capital efficiency.
Before the model, the documents. We read the filings, the footnotes, and the fine print in full. The argument is built from the source material.
Three-statement model from scratch. Unit economics, capital allocation history, and the footnotes the bankers hope you'll skip.
Reports go out only when the work is finished. We disclose our positions, then update readers as the thesis develops.
Filter by sector, or browse the full archive. Published regularly throughout the year.
One rigorous research note, delivered every Sunday. No filler. All sponsorships disclosed. Just data-driven small-cap analysis for serious investors.
